Intellia Therapeutics Q3 EPS $(1.38) Beats $(1.50) Estimate, Sales $11.99M Miss $12.45M Estimate
Portfolio Pulse from Benzinga Newsdesk
Intellia Therapeutics reported Q3 losses of $(1.38) per share, beating the analyst consensus estimate of $(1.50) by 8 percent. However, the company's quarterly sales of $11.99 million missed the analyst consensus estimate of $12.45 million by 3.68 percent.
November 09, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Intellia Therapeutics' Q3 earnings per share beat estimates, but sales fell short. This mixed result could lead to uncertainty in the market.
Intellia Therapeutics reported a better-than-expected EPS for Q3, which is a positive signal for investors. However, the company's sales missed estimates, which could be a concern. This mixed result could lead to uncertainty in the market, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100